Literature DB >> 16809903

Influence of ALA54THR polymorphism of fatty acid binding protein 2 on lifestyle modification response in obese subjects.

D A de Luis1, R Aller, O Izaola, M Gonzalez Sagrado, R Conde.   

Abstract

BACKGROUND/AIM: It has been found that the expression of fatty acid binding protein 2 (FABP2) mRNA is under dietary control. A G-to-A transition at codon 54 of FABP2 results in an amino acid substitution (from Ala 54 to Thr 54). This polymorphism was associated with high insulin resistance and high fasting insulin concentrations. The aim of our study was to investigate the influence of Thr54 polymorphism in the FABP2 protein on the response to a lifestyle modification (Mediterranean hypocaloric diet and exercise) in obese patients.
METHODS: A population of 69 obese (body mass index > 30) nondiabetic outpatients was analyzed in a prospective way. Before and after 3 months of the lifestyle modification program, indirect calorimetry, tetrapolar electrical bioimpedance measurement, blood pressure recording, serial assessment of the nutritional intake (3 days of written food records), and biochemical analysis were performed. The lifestyle modification program consisted of a hypocaloric diet (1,520 kcal; 52% carbohydrates, 25% lipids, and 23% proteins). The exercise program consisted of aerobic exercise for at least three times/week (60 min each). Statistical analysis was performed for combined Ala54/Thr54 and Thr54/Thr54 as a mutant group and wild-type Ala54/Ala54 as second group.
RESULTS: The mean age was 45.5 +/- 16.7 years, the mean body mass index was 34.1 +/- 5.1, and there were 14 males (20.3%) and 55 females (79.7%) with a weight loss of 3.17 +/- 3.5 kg (3.5%). Thirty-seven patients (53.6%) had the genotype Ala54/Ala54 (wild-type group) and 32 (46.4%) patients either the genotype Ala54/Thr54 (26 patients, 30.2%) or the genotype Thr54/Thr54 (6 patients, 16.2%). The percentage of responders (weight loss) was similar in both groups (89.2 vs. 90.6%). In the wild-type group, body mass index, weight, fat mass, low-density lipoprotein cholesterol level, and waist circumference decreased, whereas the VO2 (oxygen consumption) increased. In the mutant group, glucose, body mass index, weight, waist circumference, and systolic blood pressure decreased, and VO2 increased. No differences were detected between basal values in both groups. Only the leptin levels showed a significant decrease in the wild-type group (23.85%; p < 0.05), with no statistically significant difference in the mutant group (2.59%; NS). Resistin, tumor necrosis factor alpha, interleukin 6, insulin, and C-reactive protein remained without changes in both groups.
CONCLUSIONS: Weight loss is associated with different changes, depending on the FABP2 genotype. Carriers of the Thr54 allele have a different response than wild-type obese subjects, with a significant decrease of systolic blood pressure and glucose levels in Thr54 carriers and a significant decrease in fat mass, low-density lipoprotein cholesterol, and leptin in wild-type patients. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16809903     DOI: 10.1159/000094299

Source DB:  PubMed          Journal:  Ann Nutr Metab        ISSN: 0250-6807            Impact factor:   3.374


  11 in total

1.  Behavioral and Environmental Modification of the Genetic Influence on Body Mass Index: A Twin Study.

Authors:  Erin E Horn; Eric Turkheimer; Eric Strachan; Glen E Duncan
Journal:  Behav Genet       Date:  2015-04-18       Impact factor: 2.805

2.  A Database of Gene-Environment Interactions Pertaining to Blood Lipid Traits, Cardiovascular Disease and Type 2 Diabetes.

Authors:  Yu-Chi Lee; Chao-Qiang Lai; Jose M Ordovas; Laurence D Parnell
Journal:  J Data Mining Genomics Proteomics       Date:  2011-01-01

3.  Fatty acid-binding protein 2 Ala54Thr genotype is associated with insulin resistance and leptin levels changes after a high monounsaturated fat diet in obese non-diabetic patients.

Authors:  D A de Luis; R Aller; O Izaola; M Gonzalez Sagrado; R Conde
Journal:  J Endocrinol Invest       Date:  2013-06       Impact factor: 4.256

4.  Ala54Thr polymorphism of fatty acid binding protein 2, role on insulin resistance and cardiovascular risk factors in presurgical morbid obesity patients.

Authors:  D A de Luis; M Gonzalez Sagrado; R Aller; O Izaola; R Conde; Enrique Romero
Journal:  Obes Surg       Date:  2009-12       Impact factor: 4.129

Review 5.  Gene-environment interaction and obesity.

Authors:  Lu Qi; Young Ae Cho
Journal:  Nutr Rev       Date:  2008-12       Impact factor: 7.110

Review 6.  Association between FABP2 Ala54Thr polymorphisms and type 2 diabetes mellitus risk: a HuGE Review and Meta-Analysis.

Authors:  Chun-Jian Qiu; Xiao-Zheng Ye; Xiao-Juan Yu; Xiao-Ren Peng; Tong-Huan Li
Journal:  J Cell Mol Med       Date:  2014-11-11       Impact factor: 5.310

7.  Effects Ala54Thr polymorphism of FABP2 on obesity index and biochemical variable in response to a aerobic exercise training.

Authors:  Tae Kyung Han
Journal:  J Exerc Nutrition Biochem       Date:  2013-12-09

8.  Association of polymorphisms of genes involved in lipid metabolism with blood pressure and lipid values in mexican hypertensive individuals.

Authors:  Blanca Estela Ríos-González; Bertha Ibarra-Cortés; Guadalupe Ramírez-López; José Sánchez-Corona; María Teresa Magaña-Torres
Journal:  Dis Markers       Date:  2014-12-21       Impact factor: 3.434

Review 9.  Metabolic Adaptation in Obesity and Type II Diabetes: Myokines, Adipokines and Hepatokines.

Authors:  Kyoung-Jin Oh; Da Som Lee; Won Kon Kim; Baek Soo Han; Sang Chul Lee; Kwang-Hee Bae
Journal:  Int J Mol Sci       Date:  2016-12-22       Impact factor: 5.923

10.  The Ala54Thr Polymorphism of the Fatty Acid Binding Protein 2 Gene Modulates HDL Cholesterol in Mexican-Americans with Type 2 Diabetes.

Authors:  Lorena M Salto; Liming Bu; W Lawrence Beeson; Anthony Firek; Zaida Cordero-MacIntyre; Marino De Leon
Journal:  Int J Environ Res Public Health       Date:  2015-12-23       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.